Long-term variability of glycemic markers and risk of all-cause mortality in type 2 diabetes: the Look AHEAD study
暂无分享,去创建一个
[1] G. Ning,et al. Prognostic Significance of Long-term HbA1c Variability for All-Cause Mortality in the ACCORD Trial , 2020, Diabetes Care.
[2] E. Wan,et al. Age‐specific associations of glycated haemoglobin variability with cardiovascular disease and mortality in patients with type 2 diabetes mellitus: A 10‐ year cohort study , 2020, Diabetes, obesity & metabolism.
[3] Ming-Ju Wu,et al. The variability of glycated hemoglobin is associated with renal function decline in patients with type 2 diabetes , 2020, Therapeutic advances in chronic disease.
[4] Francesca N. Delling,et al. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association , 2020, Circulation.
[5] D. Cook,et al. Variability in Glycated Hemoglobin and Risk of Poor Outcomes Among People With Type 2 Diabetes in a Large Primary Care Cohort Study , 2019, Diabetes Care.
[6] O. Takahashi,et al. Visit-to-Visit Hemoglobin A1c Variability Is Associated With Later Cancer Development in Patients With Diabetes Mellitus , 2019, Cancer journal.
[7] Antonio Ceriello,et al. Glycaemic variability in diabetes: clinical and therapeutic implications. , 2019, The lancet. Diabetes & endocrinology.
[8] Songzhu Zhao,et al. Visit-to-Visit Glycemic Variability and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT Study , 2019, Diabetes Care.
[9] Association of HbA1C Variability and Renal Progression in Patients with Type 2 Diabetes with Chronic Kidney Disease Stages 3–4 , 2018, International journal of molecular sciences.
[10] P. Reaven,et al. Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial , 2018, Diabetes Care.
[11] Merlin C. Thomas,et al. Metabolic Karma—The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture , 2018, Diabetes.
[12] L Monnier,et al. The application of simple metrics in the assessment of glycaemic variability. , 2018, Diabetes & metabolism.
[13] Z. Bloomgarden,et al. Metabolic memory: Evolving concepts , 2018, Journal of diabetes.
[14] T. Lüscher,et al. Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA1c Levels , 2017, Diabetes.
[15] R. Testa,et al. The “Metabolic Memory” Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications , 2017, Nutrients.
[16] K. Fukuo,et al. Carotid Intima-Media Thickness and Visit-to-Visit HbA1c Variability Predict Progression of Chronic Kidney Disease in Type 2 Diabetic Patients with Preserved Kidney Function , 2016, Journal of diabetes research.
[17] Laura Lovato,et al. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study , 2016, American Journal of Nephrology.
[18] A. Goldfine,et al. Clinical Update: Cardiovascular Disease in Diabetes Mellitus Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations , 2016, Circulation.
[19] M. Rutter,et al. Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis , 2015, Diabetes Care.
[20] L. Geiss,et al. Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012. , 2015, JAMA.
[21] I. Hirsch. Glycemic Variability and Diabetes Complications: Does It Matter? Of Course It Does! , 2015, Diabetes Care.
[22] A. Sandbæk,et al. Relationship of HbA1c variability, absolute changes in HbA1c, and all-cause mortality in type 2 diabetes: a Danish population-based prospective observational study , 2015, BMJ Open Diabetes Research and Care.
[23] A. Sandbæk,et al. Relationship of HbA 1 c variability , absolute changes in HbA 1 c , and all-cause mortality in type 2 diabetes : a Danish population-based prospective observational study , 2015 .
[24] M. Woodward,et al. Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial , 2014, Diabetes Care.
[25] Hiroyuki Yanagisawa,et al. Association between HbA1c variability and mortality in patients with type 2 diabetes. , 2014, Journal of diabetes and its complications.
[26] Giuseppe Pugliese,et al. HbA1c Variability as an Independent Correlate of Nephropathy, but Not Retinopathy, in Patients With Type 2 Diabetes , 2013, Diabetes Care.
[27] Xilin Yang,et al. Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry , 2013, Diabetes/metabolism research and reviews.
[28] S. Oparil,et al. Blood Pressure Measurement Device, Number and Timing of Visits, and Intra‐Individual Visit‐to‐Visit Variability of Blood Pressure , 2012, Journal of clinical hypertension.
[29] A. Ceriello,et al. Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells , 2011, Diabetologia.
[30] Michael E. Miller,et al. ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES , 2010 .
[31] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[32] Grant D. Huang,et al. Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.
[33] S. Schinner. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .
[34] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[35] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[36] R. Testa,et al. Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients , 2008, Diabetes.
[37] K. Clément,et al. Acute Hyperglycemia Induces a Global Downregulation of Gene Expression in Adipose Tissue and Skeletal Muscle of Healthy Subjects , 2007, Diabetes.
[38] M. Ihnat,et al. Attenuated Superoxide Dismutase Induction in Retinal Cells in Response to Intermittent High Versus Continuous High Glucose , 2007 .
[39] U. Boggi,et al. Gliclazide protects human islet beta‐cells from apoptosis induced by intermittent high glucose , 2007, Diabetes/metabolism research and reviews.
[40] George A. Bray,et al. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study , 2006, Diabetes & vascular disease research.
[41] Jean-Paul Cristol,et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. , 2006, JAMA.
[42] Karen C Johnson,et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. , 2003, Controlled clinical trials.
[43] R. Marfella,et al. Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans: Role of Oxidative Stress , 2002, Circulation.
[44] J. Levy,et al. U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.